Candidiasis is treated using various treatment options such as oral medication, injection, and ointments. The condition is usually treated using over-the-counter antifungal medicines and also specific prescription-based antifungal medicines. Increasing consumer awareness about candidiasis and growing number of treatment options are major factors that are fueling growth of the candidiasis market.
The global candidiasis market is expected to witness significant growth, owing to increasing research for development of novel medications showcasing broad-spectrum antifungal activity against invasive fungal infections caused due to Candida albicans. For instance, in October 2018, researchers at the American Society for Microbiology identified a compound alexidine dihydrochloride, which has the highest antifungal and anti-biofilm activity against a diverse range of fungal pathogens, thus having a greater potential for use as a pan-antifungal drug.
However, easy access to alternative treatment methods such as over-the-counter treatments and others are expected to hinder the market growth.
- This report provides in-depth analysis of the global candidiasis market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global candidiasis market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include, Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global candidiasis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global candidiasis market
-
- Azoles
- Echinocandins
- Polyenes
- Flucytosine
-
- Candida infections of the mouth, throat, and esophagus
- Vaginal candidiasis
- Invasive/Systemic candidiasis
-
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
-
- Basilea Pharmaceutica Ltd.
- Astellas Pharma Inc.
- Grupo Ferrer Internacional, S.A.
- Pacgen Life Science Corporation
- NovaDigm Therapeutics, Inc.
- Cidara Therapeutics, Inc.
- Amplyx Pharmaceuticals Inc.
- Pfizer, Inc
